Why Is SYNDAX PHARMACEUTICA (SNDX) Stock Down Today?

Syndax Pharmaceuticals (SNDX) shares fell 26.87% to close at $10.45. The sharp decline coincided with the release of third-quarter earnings and the announcement of 19 accepted abstracts for the ASH 2026 conference.

What Happened

The company published its 2026 Q3 earnings call presentation on November 4, 2026. Simultaneously, Syndax highlighted the acceptance of 19 abstracts for its Revuforj and Niktimvo products at the ASH 2026 Annual Meeting, including seven for oral presentation. The company also announced it will host an investor event in person and via webcast on December 14, 2026. Additionally, Syndax reported inducement grants for new employees under NASDAQ Listing Rule 5635(c)(4).

What The Data Shows

The stock printed 55 fresh 52-week lows on November 4, 2026, extending a broader downward trend. Over the last eight sessions, the share price declined 21.0% from $13.22 to $10.45. The current price sits below the 52-week range of $12.79 to $25.59. Fundamentals show a market cap of $1.2 billion with revenue up 160.3% on a trailing twelve-month basis. The company remains unprofitable with a trailing twelve-month EPS of -2.37 and a net margin of -72.3%. The stock has a beta of 0.42. Recent insider activity includes one sale totaling $114,000 by Director Dennis Podlesak on October 29, 2026. There have been no insider buys in the last 90 days.

What To Watch

The next scheduled catalyst is the ASH Investor Event on December 14, 2026. Investors may also monitor the company's progress in frontline AML and commercial growth for Revuforj.